Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Pamela Manchester
Reduction in All-Cause Mortality With Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients
American Journal of Respiratory and Critical Care Medicine
Pulmonary
Critical Care
Respiratory Medicine
Intensive Care Medicine
Related publications
Single-Inhaler Triple Therapy Utilizing the Once-Daily Combination of Fluticasone Furoate, Umeclidinium and Vilanterol in the Management of COPD: The Current Evidence Base and Future Prospects
Therapeutic Advances in Respiratory Disease
Pulmonary
Respiratory Medicine
Pharmacology
Evidence-Based Review of Data on the Combination Inhaler Umeclidinium/Vilanterol in Patients With COPD
International Journal of COPD
Environmental
Public Health
Health Policy
Medicine
Pulmonary
Respiratory Medicine
Occupational Health
A Randomised Trial of Fluticasone Furoate/Vilanterol (50/25 Μg; 100/25 Μg) on Lung Function in COPD
Respiratory Medicine
Pulmonary
Respiratory Medicine
A Comparison of the Efficacy and Safety of Once-Daily Fluticasone Furoate/Vilanterol With Twice-Daily Fluticasone Propionate/Salmeterol in Moderate to Very Severe COPD
European Respiratory Journal
Medicine
Pulmonary
Respiratory Medicine
Cost–consequence Analysis of Fluticasone Furoate/Vilanterol 92/22 MCG for the Management of COPD in the Spanish NHS
ClinicoEconomics and Outcomes Research
Health Policy
Economics
Econometrics
Finance
Prs48 - Cost – Effectiveness Analysis of Vilanterol/Fluticasone Furoate for Asthma Treatment in the Russian Federation
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Fluticasone Furoate/Vilanterol Once Daily Improves Night-Time Awakenings in Asthma Patients With Night Symptoms; Post-Hoc Analyses of Three Randomized Controlled Trials
Journal of Asthma
Child Health
Allergy
Perinatology
Immunology
Medicine
Pediatrics
Pulmonary
Respiratory Medicine
Patient Considerations in the Treatment of COPD: Focus on the New Combination Inhaler Umeclidinium/Vilanterol
Patient Preference and Adherence
Pharmacology
Health Policy
Medicine
Toxicology
Social Sciences
Pharmaceutics
Corrigendum to “Fluticasone Furoate/Vilanterol (100/25; 200/25 Μg) Improves Lung Function in COPD: A Randomised Trial” [Respir Med 107 (2013) 550–559]
Respiratory Medicine
Pulmonary
Respiratory Medicine
